关键信息
-
基因名
MYDGF
- 应用
-
别名
SF20; IL25; IL27w; C19orf10; Interleukin 27 Working Designation; Interleukin-25; Stromal cell-derived growth factor SF20
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9CPT4
-
表达区间
Val25~Leu166
-
分子量
23kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
MYDGF, or Myeloid-Derived Growth Factor, is a protein that has garnered significant attention in the fields of immunology and cancer research due to its role in modulating cell growth, differentiation, and immune responses. Emerging studies suggest that MYDGF plays a crucial part in the tumor microenvironment, particularly in how myeloid cells influence tumor progression and the immune landscape. Research indicates that MYDGF can promote tumor cell survival and proliferation while potentially suppressing effective anti-tumor immune responses. The understanding of MYDGF's mechanisms of action is essential for developing targeted therapies aimed at improving cancer treatment outcomes. Moreover, MYDGF has been implicated in various inflammatory diseases, highlighting its potential as a therapeutic target beyond oncology. The exploration of MYDGF's structure, function, and pathways is key in elucidating its diverse biological roles and developing novel strategies for intervention in diseases characterized by abnormal cell growth and inflammation. As such, the study of MYDGF and its recombinant forms holds promise for advancing our understanding of complex disease mechanisms and identifying new avenues for therapeutic development.
